Investigational drug · Phase 3
Verorab
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Rabies, Rabies (Healthy Volunteers).
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 9, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
32
Any phase or sponsor naming "Verorab"
First trial start
2025
Jul 28, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Verorab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Rabies
- Rabies (Healthy Volunteers)
Largest trials
Live from ClinicalTrials.gov: studies naming "Verorab" as an intervention, largest first.
- Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in AfricaPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00866619 · 15,459 participants · Start Mar 27, 2009 · Primary completion Mar 1, 2011
Drug: Malaria Vaccine 257049; Meningococcal C Conjugate Vaccine and 3 more · For: Malaria
Sites: Ouagadougou, Burkina Faso; Lambaréné, Gabon; Kintampo, Ghana · 10 sites in all
- Efficacy and Safety of Dengue Vaccine in Healthy ChildrenPivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT00842530 · 4,002 participants · Start Feb 2009 · Primary completion Sep 2013
Drug: CYD Dengue Vaccine; Inactivated rabies virus vaccine and 1 more · For: Dengue Virus; Dengue Fever; Dengue Hemorrhagic Fever and 1 more
Sites: Bangkok, Thailand
- An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in AfricaPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02207816 · 3,084 participants · Start Sep 18, 2014 · Primary completion Jan 31, 2017
Drug: Malaria Vaccine 257049 (MALARIA-055 PRI); Meningococcal C Conjugate Vaccine (MALARIA-055 PRI) and 3 more · For: Malaria
Sites: Ouagadougou, Burkina Faso; Kisumu, Kenya; Tanga, Tanzania
- Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of AdultsPivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT04127786 · 1,708 participants · Start Oct 21, 2019 · Primary completion Mar 25, 2020
Drug: Purified vero rabies vaccine - serum free - VRVg-2; Purified inactivated rabies vaccine - Verorab® and 1 more · For: Rabies; Healthy Volunteers
Sites: Bangkok, Thailand; Khon Kaen, Thailand · 4 sites in all
- Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies VaccinePivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT01339312 · 816 participants · Start Apr 2011 · Primary completion Mar 2012
Drug: Purified inactivated rabies vaccine, serum free; Purified inactivated rabies vaccine, serum free and 2 more · For: Rabies; Rabies Virus
Sites: Nanning, China
- Proof-of-Concept Study of MSP3-LSP Vaccine to Protect Against Malaria in AfricaPivotal-lookingCompleted
Vac4AllIndustry
NCT01341704 · 800 participants · Start May 2011 · Primary completion Dec 2011
Drug: MSP3-LSP/AlOH; Verorab Vaccine · For: Malaria
Sites: Bamako, Mali
- A Phase 1/2b Study of an Investigational Malaria Vaccination Strategy in 5-17 Month Old Infants and Children in Burkina FasoPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT01635647 · 730 participants · Start Nov 2012 · Primary completion Aug 2014
Drug: ChAd63 ME-TRAP and MVA ME-TRAP; Rabies vaccine · For: Malaria
Sites: Ouagadougou, Burkina Faso
- Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in AdultsPivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT03965962 · 640 participants · Start Jul 1, 2019 · Primary completion Dec 22, 2020
Drug: VRVg-2; Purified Inactivated Rabies Vaccine and 2 more · For: Rabies (Healthy Volunteers)
Sites: Gières, France; Rennes, France
- Immunogenicity and Safety of Verorab® in a "One-week" Intradermal Post-exposure Prophylaxis RegimenPivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT01622062 · 600 participants · Start Jun 29, 2012 · Primary completion Nov 14, 2018
Drug: PVRV; PVRV and pERIG Favirab® and 1 more · For: Rabies
Sites: City of Muntinlupa, Philippines
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT03700242 · 570 participants · Start Sep 26, 2018 · Primary completion Jan 19, 2019
Drug: HDCV; HDCV and 2 more · For: Healthy Volunteers (Rabies Immunization)
Sites: Cebu City, Philippines; City of Muntinlupa, Philippines
Newest research
PubMed records naming it or its code names, newest first.
- Factors influencing rabies vaccines immunogenicity during post-exposure prophylaxis: a systematic literature search and meta-analysis.
Morelli F, Augard C, Bourhy H, et al. · Vaccine 2026
- Efficacy of ProC6C-AlOH/Matrix-M against Plasmodium falciparum infection and mosquito transmission: a phase 2, randomised, controlled human malaria infection study.
Kone M, Plieskatt J, Thienta M, et al. · Lancet Infect Dis 2026
- Full-length merozoite surface protein 1 formulated with GLA-SE adjuvant in malaria pre-exposed adults: a randomised, controlled, double-blind, parallel-group, single-centre Phase Ib trial.
Kahatano AE, Mpina M, Vanobberghen F, et al. · EClinicalMedicine 2025
- Immunogenicity and Safety of a Purified Vero Rabies Vaccine-Serum Free, Compared With 2 Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized, Controlled, Phase 3 Trial.
Pineda-Peña AC, Jiang Q, Petit C, et al. · Clin Infect Dis 2024
- Safety and immunogenicity of a serum-free purified Vero rabies vaccine in comparison with the rabies human diploid cell vaccine (HDCV; Imovax® Rabies) administered in a simulated rabies post-exposure regimen in healthy adults.
Pichon S, Moureau A, Petit C, et al. · Vaccine 2024
- Side-by-side Comparative Study of the Immunogenicity of the Intramuscular and Intradermal Rabies Post-exposure Prophylaxis Regimens in a Cohort of Suspected Rabies Virus Exposed Individuals.
Auerswald H, Maestri A, Touch S, et al. · Clin Infect Dis 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.